Predict your next investment

Other
HEALTHCARE | Biotechnology
aegera.com

See what CB Insights has to offer

Founded Year

2000

Stage

Acquired | Acquired

Total Raised

$12.3M

About gera Therapeutics

Aegera Therapeutics, located in Montreal, Canada, is a business unit of Pharmascience focused on developing targeted therapeutics to address major unmet medical needs. Aegera focuses on preclinical and early-stage clinical development through integration of "in-house" medicinal chemistry, biochemistry, cell biology, pharmacokinetics and in vivo pharmacology/efficacy. Aegera has two oncology programs in clinical development. Aegera is also dedicated to identifying novel development candidates based upon its core technologies, internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials.

gera Therapeutics Headquarter Location

810 chemin du Golf

H3E 1A8,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing gera Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

gera Therapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.